This article is concerned with the oscillation of the forced second order differ- ential equation with mixed nonlinearities（a（t）（x＇（t））γ）＇＋po（t）xγ（go（t））＋n∑t=1pi（t）｜x（gi（t））｜αi sgn x（gi...This article is concerned with the oscillation of the forced second order differ- ential equation with mixed nonlinearities（a（t）（x＇（t））γ）＇＋po（t）xγ（go（t））＋n∑t=1pi（t）｜x（gi（t））｜αi sgn x（gi（t））=e（t）,where γ is a quotient of odd positive integers αi〉0,i=1,2 ……n,a,e,and pi ∈ C（[0,∞）R）,a（t）〉0,gi：R→R are positive continuous functions on R with lim gi （t）=∞,i=0,1,……,n. Our results generalize and improve the results in a recent article by Sun and Wong[29].展开更多
背景与目的奥希替尼(Osimertinib)是美国食品和药物管理局(Food and Drug Administration,FDA)批准用于携带表皮生长因子受体(epidermal growth factor receptor,EGFR)-T790M突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)...背景与目的奥希替尼(Osimertinib)是美国食品和药物管理局(Food and Drug Administration,FDA)批准用于携带表皮生长因子受体(epidermal growth factor receptor,EGFR)-T790M突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的药物,用药前需行EGFR-T790M检测。不少患者因进展病灶隐匿或体弱无法进行组织活检错过Osimertinib治疗,本研究希望能从血清中筛查出预测EGFR-T790M耐药突变相关蛋白,为临床用药提供帮助。本研究旨在探索EGFR-T790M耐药基因相关蛋白,为临床用药提供帮助。方法本研究纳入口服易瑞沙晚期肺腺癌患者36例,在疾病进展后行组织活检,使用ARMS方法检测出EGFR-T790M突变组患者18例,非EGFR-T790M突变组18例。收集耐药患者血清,采用同位素标记相对和绝对定量标记结合二维液相色谱串联质谱蛋白组学技术筛选与EGFR-T790M耐药相关蛋白。结果筛出17种差异性蛋白,与EGFR-T790M基因突变相关上调蛋白6种,下调蛋白11种,主要参与31种生物过程,7种细胞组分,26种分子功能;反应途径中共鉴定出12种富集途径,其中富集指数最高的是凝血级联途径。结论发现与EGFR-T790M耐药相关蛋白共17种,参与凝血级联途径蛋白有望成为预测EGFRT790M耐药突变相关的生物标志物。展开更多
The authors prove the existence and uniqueness of smallest g-supersolution with an equality constrains on (y, z) for one demensional stochastic differential equations whose drift coefficients are continuous and linear...The authors prove the existence and uniqueness of smallest g-supersolution with an equality constrains on (y, z) for one demensional stochastic differential equations whose drift coefficients are continuous and linearly growing, and whose terminal conditions are square integrable.展开更多
文摘This article is concerned with the oscillation of the forced second order differ- ential equation with mixed nonlinearities（a（t）（x＇（t））γ）＇＋po（t）xγ（go（t））＋n∑t=1pi（t）｜x（gi（t））｜αi sgn x（gi（t））=e（t）,where γ is a quotient of odd positive integers αi〉0,i=1,2 ……n,a,e,and pi ∈ C（[0,∞）R）,a（t）〉0,gi：R→R are positive continuous functions on R with lim gi （t）=∞,i=0,1,……,n. Our results generalize and improve the results in a recent article by Sun and Wong[29].
文摘背景与目的奥希替尼(Osimertinib)是美国食品和药物管理局(Food and Drug Administration,FDA)批准用于携带表皮生长因子受体(epidermal growth factor receptor,EGFR)-T790M突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的药物,用药前需行EGFR-T790M检测。不少患者因进展病灶隐匿或体弱无法进行组织活检错过Osimertinib治疗,本研究希望能从血清中筛查出预测EGFR-T790M耐药突变相关蛋白,为临床用药提供帮助。本研究旨在探索EGFR-T790M耐药基因相关蛋白,为临床用药提供帮助。方法本研究纳入口服易瑞沙晚期肺腺癌患者36例,在疾病进展后行组织活检,使用ARMS方法检测出EGFR-T790M突变组患者18例,非EGFR-T790M突变组18例。收集耐药患者血清,采用同位素标记相对和绝对定量标记结合二维液相色谱串联质谱蛋白组学技术筛选与EGFR-T790M耐药相关蛋白。结果筛出17种差异性蛋白,与EGFR-T790M基因突变相关上调蛋白6种,下调蛋白11种,主要参与31种生物过程,7种细胞组分,26种分子功能;反应途径中共鉴定出12种富集途径,其中富集指数最高的是凝血级联途径。结论发现与EGFR-T790M耐药相关蛋白共17种,参与凝血级联途径蛋白有望成为预测EGFRT790M耐药突变相关的生物标志物。
基金the National Natural Science Foundation of China!(No.79790130)
文摘The authors prove the existence and uniqueness of smallest g-supersolution with an equality constrains on (y, z) for one demensional stochastic differential equations whose drift coefficients are continuous and linearly growing, and whose terminal conditions are square integrable.
